Atricure reports first quarter 2023 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced first quarter 2023 financial results. “we had an extraordinary start to 2023 driven by strength across our platforms globally. we are experiencing robust demand from physicians to treat patients and remain excited for the extensive opportunities in our marke.
ATRC Ratings Summary
ATRC Quant Ranking